ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AZN Astrazeneca Plc

12,180.00
120.00 (1.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  120.00 1.00% 12,180.00 12,194.00 12,198.00 12,332.00 12,114.00 12,116.00 1,495,832 16:35:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 31.75 186.95B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 12,060p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,704.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £186.95 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 31.75.

Astrazeneca Share Discussion Threads

Showing 5226 to 5247 of 6175 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
24/11/2021
14:13
azn gets a mention

People are now dropping like flies. Its what we all warned would happen.

jimarilo
24/11/2021
08:17
Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning
Steven R Gundry
Originally published8 Nov 2021Circulation. 2021;144:A10712

jimarilo
23/11/2021
23:32
AstraZeneca vaccine may give longer protection that is shielding UK from new Covid wave

Giving Oxford jab to elderly could be why Britain has so far avoided virus crisis hitting Europe, say experts

By
Sarah Knapton,
SCIENCE EDITOR and
Ben Riley-Smith,
POLITICAL EDITOR
23 November 2021 • 9:49pm



AstraZeneca may offer longer-lasting immunity than other vaccines, scientists have said amid claims that the jab has helped Britain avoid the latest Covid wave in Europe.

Pascal Soriot, the chief executive of AstraZeneca, said the decision to give the Oxford vaccine to older people in Britain could be one of the reasons the UK was not seeing not "so many hospitalisations relative to Europe" despite a high number of cases.

The Telegraph understands that the pharmaceutical company is preparing to release data showing that its jab offers long term T-cell immunity for older people even after antibodies wane. Mr Soriot said the immunity provided by T-cells may be "more durable".

Several countries – including France, Germany, Spain and Belgium – restricted the AstraZeneca vaccine to under-65s in the early stages of their rollouts, claiming there was not enough data to prove it worked for older people.

In France, daily infections passed 30,000 for the first time since August on Tuesday, with an increase of 63 per cent in a week. Germany confirmed it was planning to make vaccination mandatory for soldiers. The seven-day average of Covid deaths in the country is now twice that in Britain.

"European leaders had all these unfounded concerns about AstraZeneca and its use in older people," a senior government source said. "If you look at the data, you can see us using it early has been incredibly helpful in terms of protecting older and vulnerable people from this disease for longer."


More:

maxk
23/11/2021
11:10
BRYAN GARNIER CUTS ASTRAZENECA TO 'BUY' (CONVICTION BUY) - PRICE TARGET 10,500 PENCE

KEPLER CHEUVREUX CUTS ASTRAZENECA PRICE TARGET TO 9,500 (9,800) PENCE - 'BUY'

philanderer
23/11/2021
11:01
AstraZeneca's pledge to poorer nations as it seeks COVID jab profits from next year
philanderer
22/11/2021
10:23
And of course the numbers are far worse as 0-28 days after jabbing you're considered unvaccinated so all deaths from the jabs in that period aren't counted as jab deaths.

Ricky risk. No one addresses my comments sensibly . All I get are ad hominems. Why is that?

Moderate? Why do you only want good news. If the immunity from prosecution is ruled unlawful all those jab deaths and injuries would bankrupt any company. You better pray the fascism doesn't get taken down.

john nada
22/11/2021
10:07
Google "cherry picking". Does this platform have a moderator?
riskonricky
22/11/2021
08:49
LMFAO. Where's the accident data. Where's the jabbed vs unjabbed accident data?? The only data that can trusted is overall mortality as shown in the graph and the jabbed are dying at twice the rate. It's there in blue and brown.

Look I understand these facts are troubling. If you're a human and not a bot investing in a company like AZN is soul destroying.

john nada
22/11/2021
08:36
It starts during lockdown you numbskull. Of course people are having more accidents now they are doing something. Took me 10 seconds to work that out - Idiot.
riskonricky
22/11/2021
08:30
As Charlie Sheen famously said. WINNING.

That immunity from prosecution is a pretty neat trick big pharma managed to pull off. All those billions in pension payments avoided. Stunning business model.



Vaccinated English adults under 60 are dying at twice the rate of unvaccinated people the same age and have been for six months. This chart may seem unbelievable or impossible, but it's correct, based on weekly data from the British government.

The brown line represents weekly deaths from all causes of vaccinated people aged 10-59, per 100,000 people.

The blue line represents weekly deaths from all causes of unvaccinated people per 100,000 in the same age range.

I have checked the underlying dataset myself and this graph is correct. Vaccinated people under 60 are twice as likely to die as unvaccinated people. And overall deaths in Britain are running well above normal.

I don’t know how to explain this other than vaccine-caused mortality.

The basic data is available here, download the Excel file and see table 4:

john nada
18/11/2021
13:37
Greg, AZN have stated that a modest profit on vaccines going forward should
offset development costs on their antibody treatment. They don't appear to give
an indication this will be a strong profit generator for the business.

COVID obscures the high growth story emerging on the pharma side.

essentialinvestor
18/11/2021
12:56
The price has not been set for AZD7442 so how do you know that the profit is miniscule?
gregb
18/11/2021
12:53
Good shout!! - and given the minuscule profit on this re AZN it's illogical.
But that the market and there are algos at play,

Getting tempted to have a small amount.

essentialinvestor
18/11/2021
12:13
P,

And every time AZN mentions anything related to Covid it tanks!

beckers2008
18/11/2021
10:56
(Alliance News) - AstraZeneca PLC on Thursday said tests have confirmed effectiveness against Covid-19 from a one-time intramuscular dose of AZD7442 in high-risk populations.

The Cambridge, England-based pharmaceutical firm said new data from the AZD7442 Covid-19 Provent prevention and Tackle outpatient treatment phase III trials showed one 300 milligramme dose of AZD7442 reduced the risk of developing symptomatic Covid-19 compared to placebo by 83%.

The AZD7442 Provent trial is the first phase III trial designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic Covid-19, with targeted inclusion of high-risk and immunocompromised participants.

Astra highlighted that there were no cases of severe Covid-19 or Covid-19-related deaths in those treated with AZD7442 at either the primary or six-month analyses.

philanderer
17/11/2021
13:39
AZN in Oversold territory.

ASTRAZENECA : UBS reaffirms its Buy rating
11/17/2021 | 10:42am GMT

In a research note published by Michael Leuchten, UBS advises its customers to buy the stock. The target price remains set at GBX 10000.

ASTRAZENECA : Deutsche Bank reiterates its Buy rating
11/17/2021 | 12:09pm GMT

Deutsche Bank analyst Emmanuel Papadakis maintains his Buy rating on the stock. The target price remains set at GBX 10500.

beckers2008
17/11/2021
10:09
gullible thickies like Jimarilo crop up everywhere .
arja
17/11/2021
10:07
SOCGEN RAISES ASTRAZENECA PRICE TARGET TO 15,500 (15,000) PENCE - 'BUY'
philanderer
17/11/2021
03:00
Dr. David Martin
jimarilo
17/11/2021
02:58
People finally waking up to what is going on here........most people in hospital have been jabbed.....the jab is what put them there

This is not a vaccine, this is not a vaccine, this is not a vaccine

It is a gene therapy, that is designed to harm and kill you .....FACT!!

jimarilo
16/11/2021
21:32
bit more downside for AZN but getting close to chart support
arja
16/11/2021
18:49
Well I have just had a £10k bet. If its a none profit drug they are producing then whats the problem???
jackdaw4243
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older